loading page

Vaccines for Tumours: Melanoma
  • Daniel Wells
Daniel Wells
University of Oxford

Corresponding Author:[email protected]

Author Profile


This case commentary concerns a 56-year-old patient with stage III malignant melanoma which was removed but within 7 months the patient developed secondary tumours in his vertebrae. A multi-epitope vaccination was given after which the patient developed vitiligo and posterior uveitis. The topics addressed include the different types of antigens that can be expressed by malignant melanoma, how immune surveillance fails, the immunological mechanisms involved in the side effects of vaccination, and a comparison of peptide vaccination with dendritic cell immunotherapies. This commentary was created in 2015 as part of the masters programme in Molecular and Cellular Biochemistry at the University of Oxford.